Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Change in Acquisitions & Divestments (2023 - 2025)

Cytek Biosciences (CTKB) has disclosed Change in Acquisitions & Divestments for 3 consecutive years, with $76.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Acquisitions & Divestments rose 69.12% year-over-year to $76.1 million, compared with a TTM value of $292.2 million through Dec 2025, up 49.85%, and an annual FY2025 reading of $292.2 million, up 49.85% over the prior year.
  • Change in Acquisitions & Divestments was $76.1 million for Q4 2025 at Cytek Biosciences, down from $79.2 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $79.2 million in Q3 2025 and bottomed at $10.0 million in Q2 2023.
  • Average Change in Acquisitions & Divestments over 3 years is $56.3 million, with a median of $66.5 million recorded in 2025.
  • Peak annual rise in Change in Acquisitions & Divestments hit 300.0% in 2024, while the deepest fall reached 44.12% in 2024.
  • Year by year, Change in Acquisitions & Divestments stood at $54.0 million in 2023, then decreased by 16.67% to $45.0 million in 2024, then skyrocketed by 69.12% to $76.1 million in 2025.
  • Business Quant data shows Change in Acquisitions & Divestments for CTKB at $76.1 million in Q4 2025, $79.2 million in Q3 2025, and $66.5 million in Q2 2025.